All In Biotech

Drug Trial Radar · NCT05322590

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

A Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination With mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 195 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

195

Planned (sponsor's estimate)

Start

Jan 9, 2023

Primary completion

Nov 2026

Study completion Apr 2029

Sponsor

Lead sponsor
Bexion Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
ICON plc; CTI Clinical Trial and Consulting Services
First posted
Apr 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum. The study will also evaluate if the administration of BXQ-350 with mFOLFOX7 and bevacizumab may diminish oxaliplatin induced sensory neurotoxicity, enabling participants to receive the total and planned doses of mFOLFOX7. All participants will receive BXQ-350 by intravenous (IV) infusion along with standard of care doses of mFOLFOX and bevacizumab. The study is divided into two stages: Stage 1 will be open label and will enroll participants at increasing dose levels of BXQ-350 in order to determine the Stage 2 dose. Stage 2 will be blinded; participants will receive BXQ-350 at the established Stage 1 dose or placebo.

Conditions

  • Metastatic Colorectal Carcinoma
  • Neuropathy

Interventions

  • BXQ-350Drug

    BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible.

  • PlaceboOther

    Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible (Stage 2 only)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 DoseTime frame: 6 months
  2. Incidence of Treatment Emergent Adverse Events as Assessed by CTCAE v5.0Time frame: 6 months
  3. Objective Response Rate (ORR)Time frame: 6 months

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • UC Irvine Health

    Orange, California

  • Pacific Hematology Oncology Associates

    San Francisco, California

  • Sylvester Comprehensive Cancer Center, University of Miami Hospitals and Clinics

    Miami, Florida

  • The University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • St. Elizabeth Healthcare

    Edgewood, Kentucky

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky

  • University of Louisville, James Graham Brown Cancer Center

    Louisville, Kentucky

  • University Medical Center New Orleans

    New Orleans, Louisiana

  • Stony Brook Cancer Center

    Stony Brook, New York

  • Gabrail Cancer Center Research

    Canton, Ohio

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.